Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. Keeping that in mind, here are two profitable companies that leverage their financial strength to beat the competition and one that may face some trouble.
One Stock to Sell:
Sotera Health Company (SHC)
Trailing 12-Month GAAP Operating Margin: 32.8%
With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use.
Why Is SHC Not Exciting?
- Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
- Revenue base of $1.22 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Weak free cash flow margin of 0.8% has deteriorated further over the last five years as its investments increased
At $17.90 per share, Sotera Health Company trades at 17.6x forward P/E. If you’re considering SHC for your portfolio, see our FREE research report to learn more.
Two Stocks to Watch:
Insulet (PODD)
Trailing 12-Month GAAP Operating Margin: 16.9%
Revolutionizing diabetes care with its tubeless "Pod" technology, Insulet (NASDAQ: PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line.
Why Is PODD a Good Business?
- Constant currency growth averaged 26.7% over the past two years, showing it can expand globally regardless of the macroeconomic environment
- Free cash flow margin expanded by 19.9 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
- Rising returns on capital show management is finding more attractive investment opportunities
Insulet is trading at $141.05 per share, or 20.1x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
WEX (WEX)
Trailing 12-Month GAAP Operating Margin: 25.5%
Originally founded in 1983 as Wright Express to serve the fleet card market, WEX (NYSE: WEX) provides payment processing and business solutions across fleet management, employee benefits, and corporate payments sectors.
Why Are We Fans of WEX?
- Share repurchases have increased shareholder returns as its annual earnings per share growth of 20.6% exceeded its revenue gains over the last five years
- Stellar return on equity showcases management’s ability to surface highly profitable business ventures
WEX’s stock price of $182.01 implies a valuation ratio of 8.8x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
